A share price of Cardiff Oncology Inc [CRDF] is currently trading at $2.91, up 3.56%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRDF shares have gain 5.82% over the last week, with a monthly amount glided 2.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cardiff Oncology Inc [NASDAQ: CRDF] stock has seen the most recent analyst activity on September 06, 2024, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $8. On December 08, 2021, Robert W. Baird initiated with a Outperform rating and assigned a price target of $19 on the stock. H.C. Wainwright initiated its recommendation with a Buy and recommended $27 as its price target on October 22, 2020. Piper Sandler started tracking with a Overweight rating for this stock on October 08, 2020, and assigned it a price target of $25.
Cardiff Oncology Inc experienced fluctuations in its stock price throughout the past year between $2.01 and $5.64. Cardiff Oncology Inc [NASDAQ: CRDF] shares were valued at $2.91 at the most recent close of the market.
Analyzing the CRDF fundamentals
Trailing Twelve Months sales for Cardiff Oncology Inc [NASDAQ:CRDF] were 0.59M which represents -46.83% decline. Gross Profit Margin for this corporation currently stands at 0.58% with Operating Profit Margin at -108.77%, Pretax Profit Margin comes in at -102.02%, and Net Profit Margin reading is -102.0%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is -0.76 and Total Capital is -0.73. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Cardiff Oncology Inc [NASDAQ:CRDF] is 6.22. Also, the Quick Ratio is 6.22, while the Cash Ratio stands at 1.81. Considering the valuation of this stock, the price to sales ratio is 328.12, the price to book ratio is 2.73.
Transactions by insiders
Recent insider trading involved Levine James E., Chief Financial Officer, that happened on Dec 17 ’24 when 2752.0 shares were purchased. Chief Financial Officer, Levine James E. completed a deal on Dec 18 ’24 to buy 2400.0 shares. Meanwhile, Chief Financial Officer Levine James E. bought 2564.0 shares on Dec 16 ’24.
